Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Gastroenterology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Controlled Trial: Subcutaneous Versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
Gastroenterology 2021 Mar 04;[EPub Ahead of Print], S Schreiber, S Ben-Horin, J Leszczyszyn, R Dudkowiak, A Lahat, B Gawdis-Wojnarska, A Pukitis, M Horynski, K Farkas, J Kierkus, M Kowalski, SJ Lee, SH Kim, JH Suh, MR Kim, SG Lee, BD Ye, W ReinischFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.